Promising Late-stage Development Programs With Upcoming Inflections



1. Single arm Phase 2, timelines and filing plans will follow the data
2. Non-small cell lung cancer with EGFR exon 20 insertion mutations
3. Phase 1/2 studies started, incl. single agent and multiple combination studies in R/R MM

★ Orphan drug designations in at least one indication

● US Breakthrough and/or EU PRIME designations in at least one indication

● Japan SAKIGAKE and/or China Breakthrough designations in at least one indication

Late-stage program: Program in or expected to be in potential pivotal trial or having achieved proof-of-concept.

Approved

Proof-of-concept/Ph2 study readout

✓ Milestone achieved

Study start

Target Filing, anticipated year of filing for regulatory approval

All timelines are approximate estimates as of May 11, 2023, are subject to change and are subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix.

Data-driven Decisions Will Further Inform Mid-stage Pipeline Development

		FY22	FY23	FY24	Comments
GASTROINTESTINAL AND INFLAMMATION	TAK-227			Celiac disease	Recent addition with strong data in gluten challenge model.[1]
NEUROSCIENCE	TAK-861	Narcolepsy *Ph2b started* ✓		Narcolepsy (NT1 and NT2)	Advanced to Ph2b after meeting pre-specified criteria.
	danavorexton (TAK-925) ★ ●		Postanesthesia Recovery ✓ *Ph1 data presented at IARS*	Postanesthesia Recovery	Early data presented in postanesthesia model at IARS. Ph2 start in FY23.
ONCOLOGY + Cell Therapy	subasumstat (TAK-981)			Solid Tumors	POC not achieved in MSS CRC Additional solid tumor studies reading out in the next few years
	TAK-007 (CAR-NK Platform)		CD19+ hematological malignancies		On track for FY23 POC readout for cryopreserved off-the-shelf CAR-NK platform.
RARE GENETICS AND HEMATOLOGY	mezagitamab (TAK-079) ★		Immune Thrombocytopenic Purpura and IgA Nephropathy		ITP interim very encouraging, testing higher dose. Early efficacy signals in MG, await ITP and IgA Neph. readout.

Proof-of-concept (POC): Achieving proof-of-concept means obtaining clinical data sufficient to initiate pivotal trials or late-stage development. A "readout(s)" for a clinical trial occurs when Takeda has (1) received the relevant clinical data, (2) completed any necessary analysis and review of such clinical data, and (3) in instances where it is required or otherwise common convention or practice, consulted with applicable regulatory authorities regarding such clinical data. Where a readout is indicated for a class of related indications (e.g., solid tumors) involving multiple POC clinical trials, such readout occurs upon the earlier of (1) the first achievement of POC in an indication in such class, or (2) the conclusion of all of the POC clinical trials in such class.

1. Schuppan et al. N Engl J Med 2021;385:35-45

- Key early-stage milestone
- Target proof-of-concept readout
- ★ Orphan drug designations in at least one indication
- ● Japan SAKIGAKE and/or China Breakthrough designations in at least one indication
- ✓ Milestone achieved

All timelines are approximate estimates as of May 11, 2023, are subject to change and are subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix.

Important Near-Term LCM Expansions Represent Significant Growth Opportunities

	FY22	FY23	FY24
GASTROINTESTINAL AND INFLAMMATION	**ENTYVIO** ✓ Filed SC UC (US)[1]	**ENTYVIO** Target Filing SC CD (US)	**maralixibat** Target Filing ALGS, PFIC (Japan)
	ENTYVIO ✓ Filed SC CD (Japan)	**ALOFISEL** Target Filing Perianal Fistulas (US)	
ONCOLOGY	**ADCETRIS** ✓ Filed FL HL stage III (EU)	**ICLUSIG** Target Filing 1L Ph+ ALL (US)	
		CABOMETYX Target Filing CRPC (Japan)	
RARE GENETICS AND HEMATOLOGY	**LIVTENCITY** ✓ Filed R/R CMV (China)[2]	**LIVTENCITY** Target Filing R/R CMV (Japan)[2]	
	TAKHZYRO ✓ Approved Pediatric HAE (US, EU)[3]		
PLASMA-DERIVED THERAPIES	**HYQVIA** ✓ Filed CIDP (US, EU)	**HYQVIA** Target Filing PID (Japan)	**HYQVIA** Target Filing CIDP, MMN (Japan)
	TAK-880 ✓ Filed RTU IgG low IgA (US)	**TAK-880** Target Filing RTU IgG low IgA (EU)	
	CUVITRU ✓ Filed PID, SID (Japan)	**Gammagard Liquid** Target Filing CIDP (US)	
VACCINES	**NUVAXOVID** ✓ Approved (Japan)		

1. ENTYVIO SC for UC in the US is a resubmission after receiving FDA CRL in 2019
2. Post-transplant CMV infection/disease
3. TAKHZYRO pediatric HAE approved in the US, filed in the EU

Approved | Target Filing | ✓ Milestone achieved

All timelines are approximate estimates as of May 11, 2023, are subject to change and are subject to clinical and regulatory success. Table only shows selected R&D milestones and is not comprehensive. For full glossary of abbreviations please refer to appendix.

Glossary of Abbreviations

Regional Abbreviations:
CN: China; EU: Europe; JP: Japan; US: United States of America

AAD	American Academy of Dermatology
AATD	α1-antitrypsin deficiency
AATD LD	α1-antitrypsin deficiency associated liver disease
ADAMTS13	a disintegrin-like and metalloproteinase with a thrombospondin type 1 motifs 13
ADHD	attention deficit hyperactivity disorder
ALGS	Alagille syndrome
ALK	anaplastic lymphoma kinase
ALL	acute lymphocytic leukemia
AVA	Advanced Vial Access
BLA	biologics license application
BMA	bradykinin mediated angioedema
BTD	breakthrough therapy designation
CAR NK	chimeric antigen receptor natural killer cell
CD	Crohn's disease
CHMP	Committee for Medicinal Products for Human Use
CIDP	chronic inflammatory demyelinating polyradiculoneuropathy
CML	chronic myeloid leukemia
CMV	cytomegalovirus
CPF	complex perianal fistulas
CRC	colorectal cancer
CRL	complete response letter
CRPC	castrate-resistant prostate cancer
CTCL	cutaneous T-cell lymphoma
cTTP	congenital thrombotic thrombocytopenic purpura
DOAC	direct oral anti-coagulation
DS	Dravet syndrome
EGFR	epidermal growth factor receptor
EMA	European Medicines Agency
EU-M4all	EU-Medicines for all
FDA	U.S. Food & Drug Administration
FL	front line
FSI	first subject in
FY	fiscal year
GI	gastrointestinal
GvHD	graft versus host disease
H2H	head-to-head
HAE	hereditary angioedema
HemA	hemophilia A
HL	Hodgkin lymphoma
HSCT	hematopoietic stem cell transplant
IARS	International Anesthesia Research Society
IBD	inflammatory bowel disease
IgA	immunoglobulin A
IgAN	immunoglobulin A nephropathy
IgG	immunoglobulin G
IND	investigational new drug
ITP	Immune thrombocytopenic purpura
iTTP	immune thrombotic thrombocytopenic purpura
JAK	Janus kinase
IV	intravenous
iPSC	induced pluripotent stem cells
LCM	lifecycle management
LD	liver disease
LGS	Lennox-Gastaut syndrome
mCRC	metastatic colorectal cancer
mCRPC	metastatic castrate-resistant prostate cancer
MDD	major depressive disorder
MG	myasthenia gravis
MLD	metachromatic leukodystrophy
MM	multiple myeloma
MMN	multifocal motor neuropathy
mNSCLC	metastatic non-small cell lung cancer
MSA	multiple system atrophy
MSS	microsatellite stable
NASH	non-alcoholic steatohepatitis
ND	newly diagnosed
NDA	new drug application
NEJM	New England Journal of Medicine
NK	natural killer
NME	new molecular entity
NMPA	(China's) National Medical Products Administration
NSCLC	non-small cell lung cancer
NT1 or 2	narcolepsy type 1 or 2
ORR	overall response rate
PASI	psoriasis area and severity index
PCD	protein C deficiency
PEX	plasma exchange
PFIC	progressive familial intrahepatic cholestasis
Ph+ ALL	Philadelphia chromosome-positive acute lymphoblastic leukemia
PID	primary immunodeficiency
PK	pharmacokinetics
PMDA	Japan's Pharmaceuticals and Medical Devices Agency
POC	proof of concept
POGD	post-operative gastrointestinal dysfunction
PRIME	Priority medicines scheme by EMA
PTH	parathyroid hormone
QD	quaque die, every day
R/R	relapsed/refractory
RTU	ready to use
SC	subcutaneous formulation
SCD	sickle cell disease
SCPCD	severe congenital protein C deficiency
SCT	stem cell transplant
SID	secondary immunodeficiency
SLE	systemic lupus erythematosus
SOC	standard of care
STING	stimulator of interferon genes
SUMO	small ubiquitin-related modifier
TCE	T-cell engager
TEAE	treatment emergent adverse event
TKI	tyrosine kinase inhibitor
TREM2	triggering receptor expressed on myeloid cells 2
TTP	thrombotic thrombocytopenic purpura
TYK2	tyrosine kinase 2
UC	ulcerative colitis
VEGFR	vascular endothelial growth factor receptors
vWD	von Willebrand disease
vWF	von Willebrand factor
WW	Worldwide